


Parent Docket P1819R1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of David G. Lowe et al. Serial No.: 09/823,648 Filed: 30 March 2001 For: COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING GENE EXPRESSION	Group Art Unit: 1655 Examiner: Arun K. Chakrabarti  <b>CERTIFICATE OF FACSIMILE TRANSMISSION</b> I hereby certify that this correspondence is being facsimile transmitted to the US Patent Office, Group Art 1655, 703-305- 7401 on  December 20, 2001   Ann Savelli
---	--

**RESPONSE TO RESTRICTION REQUIREMENT**

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

This document is timely submitted in response to an Election Requirement mailed December 5, 2001 for which a one-month period for response was given, making the document due on or before January 5, 2002. In view of the discussion provided, reconsideration and allowance are respectfully requested.

**Restriction Requirement**

Pending claims 1-104 were restriction into the following groups under 35 U.S.C. § 121:

- I. Claims 1-40, drawn to microarray of nucleic acids, classified in class 536, subclass 22.1+.
- II. Claims 41-51, drawn to activated slides, classified in class 502, subclass 180+.

Serial No. 09/823,648

Page 2

- III. Claims 52-54, drawn to method of activation of slides, classified in class 585, subclass 906+.
- IV. Claims 55-83, drawn to method of making microarray, classified in class 536, subclass 25.3.
- V. Claims 84-104, drawn to method of nucleic acids hybridization, classified in class 435, subclass 6.

The Examiner reasons that Groups I, II, and III are unrelated; Groups II, IV, and V are unrelated; Groups III, IV, and V are unrelated; and Groups IV and V are unrelated as not disclosed as capable of use together and have different modes of operation, different functions, or different effects. Applicants respectfully traverse the rejection because a search of the literature with respect to these claims can be performed by the Examiner without undue burden, thereby making the restriction improper. In addition, Applicants respectfully point out that in paragraph 6, page 4, of the Office Action, the Examiner's statement suggesting that Groups II and IV are not disclosed as capable of use together is incorrect. In fact, claim 55 of Group IV (method of making a microarray) recites an activated slide (such as that of claim 41, Group IV) in the method. Thus, the inventions of Groups II and IV are not distinct because they can be used together.

The Examiner also reasons that Groups I & IV and Groups II & III are related as process of making and product made, but that the claims of the related groups are distinct because, for example, the products can be made by other processes.

Finally, the Examiner states that the inventions of Groups I and V are related as product and process of use, but are distinct. Applicants respectfully point out that the reason given for the distinction is incorrect. Contrary to the Examiner's statement at page 3, paragraph 4, lines 6-7, the method of nucleic acids hybridization of Group V does not produce RNA and protein or produce antisense nucleic acid for gene therapy. The method is for analyzing a target molecule attached to a

microarray (see claim 84). Thus, because the reason given for the distinction is incorrect, the restriction requirement of Groups I and V should be withdrawn.

In summary, the restriction requirement is respectfully traversed as incorrect or because the subject matter can readily be searched together without undue burden on the Examiner. Withdrawal of the restriction requirement is respectfully requested.


In the event that the restriction requirement is not withdrawn and merely to advance prosecution and allowance of claimed subject matter, Applicants elect Group I, claims 1-40, drawn to a microarray of nucleic acids.

If the Examiner has any questions, the Examiner should feel free to call the undersigned attorney at the number indicated below.

This document is timely filed within the one-month period for response. Applicant believes that no fees are due with this submission. In the unlikely event that fees are due, Applicant hereby petitions the Commissioner to authorize any extensions of time and/or to deduct fees or add credits due to our Deposit Account 07-0630 as necessary to maintain the pendency of this application.

Respectfully submitted,  
GENENTECH, INC.

Date: December 20, 2001

By:   
Dairdre I. Conley  
Reg. No. 36,487  
Telephone: (650) 225-2066



09157

PATENT TRADEMARK OFFICE  
Doc. # 102094

Genentech, Inc.  
**Genentech, Inc.**  
Genentech, Inc.

C1  
**FACSIMILE TRANSMITTAL**

1 DNA WAY  
South San Francisco, CA 94080  
(415) 225-1000  
Facsimile: (650) 952-9881

**CERTIFICATION OF FACSIMILE TRANSMISSION UNDER 37 CFR § 1.8**

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Ann Savelli

Type or print name of person signing certification

Signature Ann Savelli

Date: 12/20/01

DATE: December 20, 2001

Please deliver the following page(s) to:

NAME: **Examiner Arun Chakrabarti, Group Art 1655**  
U.S. Patent and Trademark Office  
Washington, DC 20231

Fax No.: 1-703-305-7401

FROM: Deirdre L. Conley  
Registration No.: 36,487

RE: U.S. Serial No.: 09/823,648  
Our Docket No.: P1819R1

**FAX RECEIVED**  
JAN 08 2001  
**GROUP 1600**

Number of Pages including this cover sheet - 7

Response to Restriction Requirement - 3 pages  
Request to Correct Inventorship - 2 pages (original and copy)  
Transmittal Letter - 1 page

**CONFIDENTIAL NOTE**


The documents accompanying this facsimile transmission contain information from GENENTECH, INC. which is confidential or privileged. The information is intended only for the individual or entity named on this transmission sheet. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this faxed information is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the original documents to us and the retransmission of them to the intended recipient.

If you do not receive all pages, please notify Ann Savelli at (650) 225-7039.

OFFICE  
12/20/01

Parent Docket P1819R1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  David G. Lowe et al.  Serial No.: 09/823,648  Filed: 30 March 2001  For: COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING GENE EXPRESSION	Group Art Unit: 1655  Examiner: Arun K. Chakrabarti  <b>CERTIFICATE OF FACSIMILE TRANSMISSION</b> I hereby certify that this correspondence is being facsimile transmitted to the US Patent Office, Group Art 1655, 703-305- 7401 on December 20, 2001.   Ann Savelli
---	--

TRANSMITTAL LETTER

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

1. Response to Restriction Requirement
2. Request to Correct Inventorship (dup)

In the event any additional fees are due in connection with the filing of these documents, the  
Commissioner is authorized to charge such fees to our Deposit Account No 07-0630.

Respectfully submitted.

GENENTECH, INC.

Date: December 20, 2001

By: 

Dairdre L. Conley

Reg. No. 36,487

Telephone No. (650) 225-2066



09157

PATENT TRADEMARK OFFICE